A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and ...

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...